RxDoctor Payments Data

Jacob Linh Huynh, MD

Family Medicine · Westminster, CANPI 1538466362

Payments from drug & device makers

$385in general payments, 2019–2025

Across 15 payments — averaging $25.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aimmune Therapeutics, Inc.$131
  • Gilead$122
  • AbbVie$43
  • Lilly USA, LLC$35
  • Eisai Inc.$20
  • Urovant Sciences Inc$18
  • plus $15 from 1 others

What the payments were for

  • Food & beverage$385100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$385 in reported general payments places this provider in the 55th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$133,751
Medicare patients
127
Services billed
1,888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate117$95,329
JardianceEmpagliflozin81$81,310
ProliaDenosumab40$65,466
VascepaIcosapent Ethyl120$63,521
EliquisApixaban117$58,473
TradjentaLinagliptin107$58,074
MyrbetriqMirabegron92$49,482
CreonLipase/Protease/Amylase58$49,453
ZenpepLipase/Protease/Amylase50$42,457
FarxigaDapagliflozin Propanediol36$36,125
LinzessLinaclotide67$36,008
RestasisCyclosporine55$35,231
OzempicSemaglutide28$27,065
TrulicityDulaglutide26$23,276
Dexlansoprazole DrDexlansoprazole74$20,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis, Lumigan$43$124,126194 claims
AmgenProlia$15$65,46640 claims
Aimmune Therapeutics, Inc.Zenpep$131$42,45750 claims
Lilly USA, LLCTrulicity$35$23,27626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 10,533 family medicine providers in California.

Other family medicine in Westminster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →